American Medical Technologies (North American) Ltd.
American Medical Technologies obtains new data on proprietary technology for the early detection of cancer from blood smears
American Medical Technologies (North American) Ltd. / Miscellaneous 19.03.2010 09:30 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- American Medical Technologies obtains new data on proprietary technology for the early detection of cancer from blood smears Manalapan, New Jersey | March 18, 2010 | American Medical Technology, Inc. (AMT, M20 Frankfurt Exchange) today announced that it has received new results on the efficacy of its proprietary methodology intended for the early detection of cancer and the evaluation of patient carcinogenic-resistance using image recognition technology to analyze blood smears. AMT's patent pending Blood Cell Morphometric Method TM (BCMM) is the result of 25 years of research, including historical data for hundreds of patients, that features several competitive advantages over currently available diagnostic tests. Competitive advantages include the ability to detect both the presence of cancerous disease and its location (e.g., lung cancer, stomach cancer, ovarian cancer, etc.), and the ability to evaluate a patient's anti-carcinogenic resistance, for use in selecting and assessing treatment protocols. BCMM is minimally invasive, subjecting patients only to the drawing of small samples of arterial and venous blood, and can be utilized before the onset of symptoms or the outbreak of visible lesions. AMT's BCMM methodology is designed to provide results within hours of testing. Data from recent clinical applications of BCMM demonstrates a high degree of accuracy in the early detection of cancer. Management believes that the early use of its BCMM methodology may produce valuable data for the fight against cancer and become a significant participant in the $5.2 billion market worldwide for in vitro cancer diagnostic tests. The application of BCMM may even impact across the spectrum of available cancer treatments, a market which has been estimated to represent $219.2 billion in annual costs. About American Medical Technologies, Inc. American Medical Technologies is in the process of developing its patented Blood Cell Morphometric Method TM (BCMM) methodology in order to commercialize safe and effective methods for the early diagnosis of cancer. AMT is committed to changing the practice of medicine by helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses by advancing science in a way that will dramatically improve people's lives. Please visit AMT at www.americanmedtec.com to learn more about our pioneering science and innovative company. Please contact our offices at 1-800-239-5AMT (5268) or email investor@americanmedtec.com 19.03.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found